“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.
James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology
January 19th 2023“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
2 Clarke Drive
Cranbury, NJ 08512